Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease

@article{Burn2006EffectsOR,
  title={Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease},
  author={David J. Burn and Murat Emre and Ian G. McKeith and Peter Paul De Deyn and Dag Aarsland and Chuanchieh Hsu and Roger M. Lane},
  journal={Movement Disorders},
  year={2006},
  volume={21}
}
We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). This was a 24‐week double‐blind placebo‐controlled study. Primary efficacy measures were the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) and Alzheimer's Disease Cooperative Study–Clinician's Global Impression of… 
Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
TLDR
Hallucinations predicted greater treatment responses to oral rivastigmine, and interaction testing suggested that differences in treatment effects were significant between hallucinators and non-hallucinators.
Evaluating Rivastigmine in Mild-to-Moderate Parkinson’s Disease Dementia Using ADAS-Cog Items
TLDR
Overall, rivastigmine was associated with improvements on individual cognitive items and general cognitive domains and showed significant effects versus placebo on all domains: memory, language, and praxis.
Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences.
TLDR
The magnitude of effect with rivastigmine versus placebo is quantitatively comparable in patients with AD and PD, but the treatment effect tended to be one of stabilization in AD, while in PDD improvements over baseline were seen.
Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson’s Disease Dementia
TLDR
Rivastigmine did not induce clinically significant exacerbation of motor dysfunction in patients with PDD and posthoc analysis showed that similar improvements in the symptoms of dementia, including the ability to perform activities of daily living, were seen regardless of whether exacerbations of tremor was reported during the study.
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients
TLDR
Elevated homocysteine was associated with greater rivastigmine treatment differences than normal/low homocy steine, and was associatedwith greater rvastigmin treatment differences more than normal /low homocrysteine.
Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study
TLDR
Rivastigmine in PD‐MCI showed a trend effect for improvements on a global rating of cognition, disease‐related health status, and anxiety severity, and significant improvement on a performance‐based measure of cognitive abilities.
Rivastigmine in Parkinson’s disease dementia
TLDR
There is evidence that PDD is associated with a cholinergic deficit, supporting the therapeutic role of cholinesterase inhibitors, which are already first-line agents in the treatment of Alzheimer’s disease.
Management of visual hallucinations in dementia and Parkinson’s disease
TLDR
Atypical antipsychotics were frequently studied, but with the exception of clozapine in Parkinson’s disease dementia, results were equivocal and there was some evidence that acetylcholinesterase inhibitors may help visual hallucinations.
Rivastigmine for the Treatment of Parkinson’s Disease Dementia
TLDR
Rivastigmine is a safe and effective symptomatic treatment for PDD conferring benefits with respect to cognition, function and overall clinical outcome and the comparable efficacy to other cholinesterase inhibitors is established.
Rivastigmine in Parkinson's disease dementia
TLDR
A transdermal patch which gradually releases rivastigmine over the application period is now available for use in mild to moderate dementia associated with Parkinson's disease and Alzheimer's disease.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Rivastigmine for dementia associated with Parkinson's disease.
TLDR
Rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor; however, the differences between these two groups were moderate and similar to those reported in trials of rivastIGmine for Alzheimer's disease.
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
TLDR
Findings indicate that, when minor hallucinations are included, the total prevalence of hallucinations in Parkinson's disease is much higher than previously reported, and a simple side-effect of dopaminergic treatment is not sufficient to explain the occurrence of all visual hallucinations.
Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
TLDR
A systematic review of double-blind, placebo-controlled, randomized controlled trials (RCTs), meta-analyses of medication efficacy in the treatment of patients diagnosed with dementia and experiencing neuropsychiatric symptoms found little benefit and some evidence for harm for typical (or conventional) agents.
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias.
TLDR
An operationalized evaluation of severe NSR blind to diagnosis confirmed the high prevalence in DLB and identified high frequencies in Parkinson's disease and PDD with important implications for clinical practice.
A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease.
TLDR
DLB patients were significantly more likely to experience multiple VH that persisted over follow-up and there were no significant differences in the other phenomenological characteristics including whether the hallucinations moved, the time of day that they were experienced, their size, the degree of insight, and whether they were complete.
Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia
TLDR
Results suggest that an imbalance between monaminergic and cholinergic transmitters is involved in hallucinogenesis in the human brain.
Longitudinal outcome of Parkinson’s disease patients with psychosis
TLDR
It appears the prognosis has improved with atypical antipsychotic therapy based on the finding that 28% of NH patients died within 2 years compared with 100% in a previous study done prior to availability of this treatment.
Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism.
  • D. Smith, M. Beier
  • Medicine
    Journal of the American Medical Directors Association
  • 2004
TLDR
Federal Guidelines (OBRA ‘87) indicate that the use of antipsychotics for behavior problems in dementia in the absence of true psychosis is to be discouraged, and the recently released American Academy of Neurology Guidelines suggest that atypical agents could be better tolerated compared with traditional agents.
Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
TLDR
Of the agents reviewed, the atypical antipsychotics risperidone and olanzapine currently have the best evidence for efficacy, however, the effects are modest and further complicated by an increased risk of stroke.
Dementia associated with Parkinson's disease
  • M. Emre
  • Medicine
    The Lancet Neurology
  • 2003
TLDR
The main pathology seems to be Lewy-body-type degeneration with associated cellular and synaptic loss in cortical and limbic structures and Alzheimer's disease-type pathology is commonly associated with dementia but less predictive.
...
1
2
3
...